The role of γ-aminobutyric acid B (GABA B ) receptors in the generation and maintenance of bicuculline-induced epileptiform activity in rat neocortical slices was studied using electrophysiological methods. A block of GABA B receptors in the presence of functional GABA A receptor-mediated inhibition was not sufficient to induce epileptiform activity. In the presence of the GABA A receptor antagonist bicuculline (10 µM) and at suprathreshold stimulation, the GABA B receptor antagonist CGP 35348 (10-300 µM) significantly potentiated epileptiform activity. With stimulation at threshold intensity, low concentrations of CGP 35348 (10-30 µM) potentiated bicucullineinduced activity, whereas higher concentrations (100-300 µM) invariably led to a reversible suppression of stimulus-evoked epileptiform discharges. CGP 35348 also enhanced picrotoxin-induced epileptiform activity, but at higher concentrations it was considerably less effective in suppressing such epileptiform discharges. The GABA uptake inhibitor nipecotic acid partially mimicked the actions of CGP 35348: with stimulation at threshold intensity, it reversibly suppressed bicuculline-induced epileptiform field potentials, but it did not influence epileptiform activity induced by picrotoxin. We conclude that a postsynaptic blockade of GABA B receptors induces an amplification of epileptiform activity in neocortical slices disinhibited by GABA A receptor antagonists. An additional blockade of presynaptic GABA B receptors, especially under conditions of weak stimulation of the neurons, reduces the inhibitory auto-feedback control of GABA release, leading to a displacement of competitive antagonists from the postsynaptic GABA A receptor and hence, to a suppression of epileptiform activity induced by competitive GABA A receptor antagonists.
Introduction
The function of the cerebral cortex critically depends on the balance between excitatory and inhibitory mechanisms. Disturbances in this balance, e.g. an increase in excitation and/or a reduction in inhibition, often result in epileptic seizures (Dichter & Ayala, 1987) and subsequently in irreversible neuronal damage (Siesjö & Wieloch, 1986) . In the central nervous system, the amino acid γ-aminobutyric acid (GABA) acts as the major inhibitory neurotransmitter and plays a key role in controlling neuronal excitability. A decline in the efficacy of the GABAergic system leads to neuronal hyperexcitability and seizure disorders (Roberts, 1986; Olsen et al., 1992) .
This so-called 'GABA hypothesis' implies that alterations in one or more components of the GABAergic system might be sufficient to primarily cause epileptiform discharges or to facilitate the generation of epileptiform activity, which is induced by the malfunction of other processes necessary to regulate excitability. Independent of the primary disturbance, it has been shown that many types of seizure disorders are associated with morphological (Sloper et al., 1980; Ribak et al., 1986; Sloviter, 1987) , metabolic (Kamphuis et al., 1989; Janjua et al., 1991) and functional (Bekenstein & Lothman, 1993) changes in the GABAergic system. Thus, many animal models of Correspondence: B. Sutor, as above. E-mail: bernd.sutor@lrz.uni-muenchen.de
Received 17 December 1997 , revised 21 May 1998 , accepted 25 June 1998 epilepsies, in vivo and in vitro, are based on the disruption of GABAergic synaptic transmission (Fisher, 1989) .
Inhibitory postsynaptic potentials (IPSPs) in mammalian neocortical neurons are almost exclusively mediated by GABA via the GABA A or GABA B receptor subtype (Connors et al., 1988; McCormick, 1989) . The blockade of GABA A receptors by selective antagonists results in paroxysmal depolarizing shifts (Gutnick et al., 1982) , which represent the correlate of epileptiform activity at the single cell level. For a long time, the analysis of the role of the different GABA receptors in generating pathophysiological activity was mainly focused on the GABA A receptor, due to the lack of selective GABA B receptor antagonists (Bonanno & Raiteri, 1993; Bowery, 1989) . Meanwhile, a number of such antagonists have become available and the physiological role of GABA B receptors has been studied in detail (for review see Misgeld et al., 1995) . In human neocortical pyramidal cells, the long-lasting and potassium-dependent IPSP was blocked by the GABA B receptor antagonist phaclofen, indicating the involvement of this receptor subtype in the generation of the late IPSP (McCormick, 1989) .
With regard to the induction and maintenance of seizure activity, a participation of GABA B receptors in different model systems of absence seizures has been proposed (Marescaux et al., 1992; Hosford et al., 1992; Snead III, 1992) and in a model of chronic temporal lobe epilepsy, Mangan & Lothman (1996) described the dysfunction of both pre-and postsynaptic GABA B receptor-mediated processes. Furthermore, GABA B receptor antagonists prolonged paroxysmal depolarizing shifts induced by GABA A receptor antagonists in hippocampal (CGP 35348, Karlsson et al., 1992; Scanziani et al., 1994) and neocortical (phaclofen, McCormick, 1989) pyramidal cells. During a study on the spread of epileptiform activity in neocortical slices, we observed, under certain experimental conditions, that the selective GABA B receptor antagonist CGP 35348 (Olpe et al., 1990) was able to block bicuculline-induced epileptiform activity evoked by electrical stimulation. We therefore investigated to what extent activation of GABA B receptors contributes to the initiation and maintenance of epileptiform activity in adult rat neocortex in vitro. Some of these results have been published previously in abstract form (Sutor & Luhmann, 1992) .
Materials and methods

Slice preparation and maintenance
The techniques for preparing and maintaining rat neocortical slices in vitro were similar to those described previously from this laboratory (Sutor et al., 1994) . In brief, adult Wistar rats (120-160 g, Charles River, Sulzfeld, Germany) were anaesthetized with ether (Merck, Darmstadt, Germany) and decapitated. The brain was removed and stored for 1 min in ice-cold oxygenated artificial cerebrospinal fluid (ACSF). From each hemisphere, two-three coronal slices of 500 µm thickness were cut using a vibratome (Campden Instruments, London, UK) and stored in ACSF at room temperature. Following an incubation period of at least 1 h, one slice was transferred to the recording chamber where it was kept submerged in ACSF by means of two nylon meshes. The ACSF contained (in mM): NaCl, 125; KCl, 3; NaH 2 PO 4 , 1.25; CaCl 2 , 2; MgCl 2 , 1.3; NaHCO 3 , 25; glucose, 10. The solution was saturated with a mixture of 95% O 2 and 5% CO 2 to maintain oxygen supply and to achieve a pH of 7.4, respectively. The temperature of the ACSF in the recording chamber was held between 31 and 32°C. The flow rate was adjusted to 5 mL/min.
Stimulation and electrophysiological recordings
Extra-and intracellular recordings were made in layers II and III of the rat frontal cortex with microelectrodes filled with 1 M NaCl (electrode resistance 2-5 MΩ) and 2 M potassium acetate (75-120 MΩ), respectively. Orthodromic synaptic responses were elicited by electrical stimulation of the underlying layer V/VI with a bipolar stimulating electrode connected to an isolation unit. In the absence of bicuculline, stimulation was performed using constant current pulses of 50-100 µs in duration at a frequency of 0.05 Hz. This stimulus frequency allowed stable recordings of K ϩ -dependent late IPSPs without a decline in the amplitude (see Howe et al., 1987a) . In the presence of bicuculline, the stimulus frequency was reduced to 1-2 per min. Under these conditions, the threshold intensity was defined as the minimum stimulus strength necessary to evoke epileptiform activity over prolonged periods of time (60-80 min) with only a few (two-three) response failures. In some experiments, we used double pulse stimulation to obtain stable recordings of epileptiform activity. In these cases, the stimulus frequency was 1 every 2 min and the inter-pulse interval was 40 ms. The stimulus strength was adjusted to evoke a signal in response to the second stimulus.
Intracellular signals were recorded with a switched current-and voltage-clamp amplifier (SEC 10L, npi, Tamm, Germany) in bridge mode. Recordings were made exclusively from neurons identified as regular spiking cells (McCormick et al., 1985) . Data were displayed on a storage oscilloscope and digitized on-line using a PC in conjunction with a laboratory interface (CED 1401, Cambridge, UK).
Optical recordings
Multi-site optical recordings of evoked epileptiform activity were made according to the method which has been described in detail previously (Sutor et al., 1994) . In brief, slices were stained for 30 min with the voltage-sensitive fluorescent dye RH 414 (30 µM, Molecular Probes, Eugene, OR, USA). Up to 20 recordings sites were arranged in an area of 1 mm 2 covering the neocortical layers II-V. Fluorescence was induced by exciting the dye with light from a krypton laser (Innova 90 K, Coherent, Palo Alto, CA, USA; wavelength: 530.9 nm) and, after passage through a cut-off filter (590 nm), the emitted light was registered using a single photodiode. The laser beam was guided from point to point by means of acousto-optical deflectors (Isomet, Springfield, VA, USA) at a sampling rate of 1 kHz. Effects due to dye bleaching, inhomogeneous staining and laser instabilities were compensated as described previously (Sutor et al., 1994) .
Drugs
The competitive GABA A receptor antagonist bicuculline methiodide (Sigma, Deisenhofen, Germany), the non-competitive GABA A receptor antagonist picrotoxin (Sigma, Deisenhofen, Germany), the GABA uptake inhibitor nipecotic acid (Sigma, Deisenhofen, Germany), the N-methyl-D-aspartate (NMDA) receptor antagonist D-2-amino-5-phosphonovaleric acid (D-2-APV, Sigma, Deisenhofen, Germany) and the GABA B receptor antagonist CGP 35348 (kindly provided by Dr Olpe from Ciba-Geigy, Basel/Switzerland) were added to the bathing solution. Nominally magnesium-free (Mg 2ϩ -free) solutions were prepared by omitting MgCl 2 from the normal ACSF. All values are given as mean Ϯ standard error of the mean (SEM).
Results Figure 1A -D shows intracellular recordings obtained from a regular spiking neuron located in the supragranular layers of the neocortex. In the presence of bicuculline, stimulation at threshold intensity evoked a large paroxysmal depolarization (Fig. 1A, Bic) . Before application of bicuculline, the same stimulus elicited only a small, short-lasting depolarizing response (Fig. 1A, Con) . Application of CGP 35348 at a concentration of 30 µM generated a slow depolarizing component following the initial bicuculline-induced paroxysmal depolarization (Fig. 1B) . This CGP 35348-induced second component lasted up to 5 s and gave rise to repetitive single burst discharges. Increasing the concentration of the GABA B receptor antagonist to 100 µM led to a potentiation of both the first and the second signal component, and to a decrease in the latency of the second component (Fig. 1C) . However, at this concentration and with stimulation at threshold intensity, we observed that most of the stimuli did not produce an epileptiform response (see arrow in Fig. 1C ). This suppression of bicuculline-induced epileptiform responses did not occur upon an increase in stimulus strength to suprathreshold levels. Removing CGP 35348 from the bathing medium reversed all actions of the compound. These actions of CGP 35348 were observed in all neurons tested (n ϭ 18, resting membrane potential: -84.2 Ϯ 2.4 mV, input resistance: 37.8 Ϯ 8.9 MΩ). Thus, the GABA B receptor antagonist altered bicuculline-induced epileptiform activity in two different FIG. 1. CGP 35348 potentiates intracellularly recorded epileptiform activity. (A) Stimulus-evoked epileptiform discharge in a neocortical neuron (RMP ϭ -85 mV) in the presence of bicuculline (Bic, 10 µM). Stimulation strength (125 µA) corresponded to threshold intensity. The stimulus response obtained before application of bicuculline is shown superimposed (Con) (B) Ten minutes after application of 30 µM CGP 35348, repetitive discharges following the initial burst response were observed. The total duration of the epileptiform potential was approximately 6 s. (C) An increase in the concentration of the antagonist to 100 µM led to an enhancement of the stimulus-induced depolarization associated with an inactivation of action potentials (upper trace). However, at this concentration, many of the stimuli failed to produce a response (lower trace, arrow). (D) Following washout of the antagonist, the effect reversed and the evoked activity was comparable to control recordings. CGP 35348 neither influenced membrane potential nor input resistance in this and all other neurons tested. (E) Extracellularly recorded field potential in the presence of bicuculline (10 µM). The stimulus strength (150 µA) was set to twice the intensity necessary to induce a consistent response (see inset). The diagram shows the area of field potentials measured in the absence and presence of different concentrations of CGP 35348. The area was determined within a constant time window of 1 s following onset of the signal. (F) Amplitude of the field potentials (second peak) at different concentrations of CGP 35348. CGP 35348 (100 µM) produced an almost 100% increase in the area of the response, but a non-significant effect on its amplitude.
ways: (i) CGP 35348 potentiated paroxysmal depolarizations. This effect was concentration dependent and could be observed predominantly with stimulation at suprathreshold intensity; (ii) at higher concentrations and with stimulation at threshold intensity, the compound suppressed epileptiform activity.
Potentiating effect of CGP 35348 on bicuculline-induced epileptiform activity
To characterize the potentiating effect of CGP 35348 on bicucullineinduced epileptiform activity, field potentials were recorded in the presence of 10 µM bicuculline. The stimulus strength was set to twice the threshold intensity (Fig. 1E, inset) . Application of CGP 35348 led to an increase in the area of the epileptiform field potential (Fig.  1E ). This effect was concentration dependent and reversible following washout of the compound (Fig. 1E ). Because measurements of the peak amplitude revealed no significant drug-induced changes (Fig.  1F ), the increase in area of the epileptiform field potential can be attributed to late signal components unmasked by CGP 35348.
These CGP 35348-induced late signal components evoked by suprathreshold stimulation in the presence of bicuculline were at least partly mediated by NMDA receptors. Figure 2A -F shows optical recordings of evoked epileptiform activity following the cumulative application of bicuculline (10 µM, Fig. 2A ,D), CGP 35348 (100 µM, Fig. 2B ,E) and D-2-APV (30 µM, Fig. 2C,F) , respectively. The measurements were performed as described in a previous paper (Sutor et al., 1994) . In the slice preparation, 20 recording sites were positioned in an area of 1 mm 2 which covered the cortical layers II-V. The most dorsal row of recording points (1, 6, 11 and 16, see The diameter of each recording spot was 80 µm. A decrease in fluorescence, which corresponds to a depolarization, was plotted in the upward direction. Fluorescence changes are given as percent deviations from the background (for details see Sutor et al., 1994) . Arrows indicate the time point of stimulation. The stimulation electrode was located at the border white matter/ layer VI, close to recording position 10. Stimulus intensity was 300 µA (suprathreshold). The basis of the diagrams shown in (G)-(I) represent the scanning area and the bars give the values of the area determined at a given recording site.
dye RH 414 and laser scanning microscopy (see Materials and methods, and Sutor et al., 1994) . In the presence of 10 µM bicuculline, stimulus-evoked epileptiform activity was observed at all recording sites ( Fig. 2A,D,G) . The characteristics of these signals were similar to those described previously (Sutor et al., 1994) . Following application of CGP 35348 (30-100 µM), a large increase in the signal area was observed at all recording sites (Fig. 2B,E,H) . The large late components of the optical signals obtained following application of CGP 35348 could be, to a large extent, blocked by the NMDA receptor antagonist D-2-APV (Fig. 2C,F,I ). These experiments (n ϭ 18) demonstrate that CGP 35348 potentiates bicuculline-induced epileptiform activity by unmasking a late NMDA receptor-dependent signal component. Furthermore, since the scanning area covered a region of the slice corresponding to layers II-V, we conclude that the effect of the GABA B receptor antagonist is independent of possible inhomogeneities in GABA B receptor distribution within the cortical layers (van Brederode & Spain, 1995) . Similar to the observations made during intra-and extracellular recordings, we encountered response failures in the presence of CGP 35348 when stimulating with current strengths equal to or close to threshold intensity.
The potentiating effect of CGP 35348 on bicuculline-induced epileptiform activity is most probably due to a blockade of K ϩ -dependent IPSPs mediated by postsynaptic GABA B receptors (McCormick, 1989 , Metherate & Ashe, 1994 . In the absence of bicuculline, CGP 35348 (30 µM) reduced the amplitude of late K ϩ -dependent IPSPs and increased the input resistance measured during these IPSPs (data not shown). Although CGP 35348 increased neuronal excitability through a reduction of late IPSPs, it did not induce epileptiform activity in any of the recorded cells. Furthermore, we have tested the effects of different concentrations (30 µM, n ϭ 28; 100 µM, n ϭ 44) of the antagonist on field potentials in superficial layers evoked by stimulation of lower layers, and in no case could we induce epileptiform activity.
In rat neocortical neurons, the GABA B receptor agonist baclofen exerts two different and independent effects (Howe et al., 1987b) : (i) a postsynaptic action by increasing a potassium conductance leading to a hyperpolarization (Fig. 3A) and (ii) a presynaptic action which is expressed in a reduction in the amplitude of both EPSPs and IPSPs (Fig. 3A) . In five neurons, we investigated the actions of CGP 35348 on these two effects. Following application of baclofen at a concentration of 3 µM, we observed a hyperpolarization of 3-5 mV and a significant decrease in input resistance of about 25% (Fig.  3A,B) . At the same time, the amplitude of the stimulus-evoked postsynaptic potential, which was composed of both EPSP and depolarizing Cl --dependent IPSP (see also : Howe et al., 1987b , Connors et al., 1988 , was found to be reduced by more than 75% (Fig. 3A,C) . Application of 30 µM CGP 35348 in the presence of 3 µM baclofen led to an almost complete reversal of the hyperpolarization and a reduction in the magnitude of the decrease in input resistance, although, in comparison to control recordings, there was still a statistically significant difference (Fig. 3B ). In addition, the baclofen-induced depression of the amplitude of the postsynaptic potential declined, however, the amplitude was still about 40% of control values (Fig. 3C) . Application of CGP 35348 at a concentration of 100 µM (in the presence of baclofen) completely blocked the baclofen-induced membrane hyperpolarization and resistance decrease (Fig. 3A,B) . In contrast, the amplitudes of the postsynaptic potentials were still found to be depressed by 25-30% (Fig. 3A,C) . A total block of the presynaptic baclofen action could be achieved upon application of CGP 35348 at a concentration of 300 µM (data not shown). The effects of both baclofen and CGP 35348 were reversible by washout of the drugs. These experiments show that CGP 35348 at a concentration of 100 µM is sufficient to completely block postsynaptic GABA B receptors, but insufficient to prevent the action of baclofen on presynaptic GABA B receptors.
Inhibitory effect of CGP 35348 on bicuculline-induced epileptiform activity
With stimulation at threshold intensity and at concentrations of CGP 35348 equal to or larger than 100 µM (see Fig. 1A-D) , we observed that the GABA B receptor antagonist inhibited bicuculline-induced epileptiform activity. In order to determine the exact conditions under which CGP 35348 reliably produced response failures, we elicited bicuculline-induced epileptiform field potentials at a rate of 1 every FIG. 4 . Effects of 30 µM and 100 µM CGP 35348 on epileptiform field potentials evoked by different stimulus intensities. The recordings were performed in the presence of bicuculline (10 µM). In each panel, five superimposed traces are shown. These signals were subsequently recorded at a rate of 1 every 2 min, thereby covering the test period of 10 min. (A) Following the addition of 30 µM CGP 35348 to the ACSF, a prolongation of the field potentials was observed. However, occasionally, the stimulus failed to produce a response. An increase in the concentration of the antagonist to 100 µM led to a complete suppression of the evoked field potentials. This effect was reversible upon removal of CGP 35348 from the ACSF. (B) and (C) Same experimental protocol, but at higher stimulus intensities (100 and 300 µA, respectively). Note the lack of response failures in (B) and (C), and the increase in synchronization with increasing stimulus intensity.
2 min at different stimulus strengths. Figure 4 depicts such an experiment (n ϭ 5 slices). At threshold intensity (Fig. 4A) , every stimulus evoked a response within a control period of 10 min. In two out of the five slices tested, one response failure was observed in each slice during the 10 min control period (consisting of five stimuli). This results in a 'failure probability' of 0.08 (n ϭ 5 slices, 'failure probability' ϭ number of response failures within the test period in all slices tested/number of stimuli applied within the test period in all slices tested). Following the addition of CGP 35348 (30 µM) and an equilibration period of 15 min, only two stimuli produced a response within the test period of 10 min. In comparison to the control, these responses were found to be potentiated (Fig. 4A) . The other three stimuli failed to induce an epileptiform field potential ('failure probability': 0.36, n ϭ 5 slices). Upon an increase in the concentration of CGP 35348 to 100 µM, almost no responses were observed within the test period (failure probability: 0.92, n ϭ 5 slices). Following washout of CGP 35348, the epileptiform discharges recovered, at least partially. At higher stimulus intensities (Fig. 4B,C CGP 35348 produced a potentiation of the epileptiform field potentials. However, no response failures were observed at any concentration of the GABA B receptor antagonist at these stimulus strengths. Thus, response failures occurred only at stimulation intensities close to threshold, and their incidence increased with the concentration of CGP 35348. Because stimulation at suprathreshold intensity evoked epileptiform potentials in every case independent of the presence and absence of CGP 35348 (Fig. 4B,C) , GABA B receptor antagonistinduced alterations in refractoriness can be excluded as a possible cause for the suppression of epileptiform discharges elicited by stimulation at threshold intensity.
To analyse the time course of the depressing effect of CGP 35348 on bicuculline-induced epileptiform activity, we evoked field potentials by double pulse stimulation using a pulse interval of 40 ms (see Materials and methods). The stimulus intensity was adjusted to threshold, i.e. at a strength which reliably produced a response to the second stimulus (Fig. 5A, control) . Under these conditions, stable epileptiform discharges could be evoked by stimulation at threshold intensity for long control periods (60-80 min) with almost no response failures (Fig. 5B) . Application of CGP 35348 at a concentration of 100 µM led to a transient increase in the area of the epileptiform potential (Fig. 5A,B) . Fifteen minutes after the start of the application, the stimulation was no longer effective in producing epileptiform responses (Fig. 5A,B) . This effect of CGP 35348 was reversible following washout of the drug (Fig. 5B ). In all slices tested in this way (n ϭ 4), CGP 35348 (100 µM, applied for 30 min) induced a complete suppression of epileptiform field potentials evoked by stimulation at threshold intensity.
In the next step, we investigated whether the action of CGP 35348 depended on the convulsive agent used to induce epileptiform activity. Therefore, we repeated the experiments described in Fig. 5A and B in the presence of the non-competitive GABA A receptor antagonist picrotoxin (Fig. 5C ) or following removal of Mg 2ϩ from the bathing medium (Fig. 5D ). In the presence of 50 µM picrotoxin (n ϭ 5 slices), 100 µM CGP 35348 produced a large potentiation of the epileptiform field potentials and a clear increase in the number of response failures (Fig. 5C ). In the case of picrotoxin, the response failures were probably due to enhanced and prolonged refractoriness, since epileptiform responses detected in the presence of picrotoxin and CGP 35348 often consisted of several repetitive discharges lasting up to 10 s (see Fig. 6B, last panel) . However, we never observed a complete block of epileptiform discharges. About 50% of the stimuli were still successful in evoking epileptiform activity. Another difference between the action of CGP 35348 in the presence of picrotoxin, as compared to in the presence of bicuculline, was the relatively fast reversal of the action of CGP 35348. Despite the long application period (30-40 min, see Fig. 5C ), the effect of CGP 35348 with picrotoxin reversed within 10-15 min following removal of the drug, whereas in the presence of bicuculline, the reversal of the antagonistic effects took 30-40 min (Fig. 5B) . In nominally Mg 2ϩ -free ACSF, neither 30 nor 100 µM CGP 35348 influenced the expression of stimulus-evoked epileptiform responses, indicating that GABA B receptor blockade did not profoundly influence NMDA receptordependent epileptiform activity in the neocortex (Fig. 5D) .
Because changes in refractoriness could be excluded as a possible cause for the failures of bicuculline-induced epileptiform discharges in the presence of CGP 35348 and with stimulation at threshold intensity, we hypothesized that these failures might be due to a presynaptic effect. By inhibition of GABA B receptors located on GABAergic terminals, CGP 35348 may enhance the free GABA concentration in the vicinity of the GABA A receptors, thereby increasing the possibility of displacing the competitive antagonist bicuculline from the binding site. Consequently, the efficacy of GABAergic inhibition might become sufficient to suppress epileptiform discharges. If this is the case, then an increase in the extracellular free GABA concentration by GABA uptake blockade should mimic the effect of CGP 35348, but only in the presence of bicuculline and not in the presence of the non-competitive GABA A receptor antagonist picrotoxin. Figure 6 shows examples of experiments testing this hypothesis (n ϭ 4 slices in bicuculline; n ϭ 4 slices in picrotoxin). In the presence of bicuculline, an epileptiform field potential was evoked using threshold intensity (Fig. 6A) . Upon application of the GABA uptake blocker nipecotic acid, the epileptiform response was found to be reversibly blocked (Fig. 6A,C) . Subsequent application of CGP 35348 (100 µM) also inhibited these responses (Fig. 6A) . In contrast, nipecotic acid did not affect epileptiform activity induced by picrotoxin (Fig. 6B,D) , and application of CGP 35348 following washout of nipecotic acid led to a large potentiation of the picrotoxininduced epileptiform field potential (Fig. 6B) .
Discussion
The development of selective GABA B receptor antagonists allowed a more detailed analysis of the physiological and pathophysiological role of GABA B receptors in the central nervous system (for review see Caddick & Hosford, 1996; Misgeld et al. 1995; Bittiger et al., 1993) . It is generally accepted that GABA B receptors exert their control on neuronal excitability via both presynaptic and postsynaptic mechanisms. GABA B receptor-mediated, potassium-dependent IPSPs have been described in a variety of CNS regions. The generation of these potentials involves G-proteins. In addition to this postsynaptic action, GABA B receptors regulate the presynaptic release of neurotransmitters most probably by affecting calcium channels located on nerve terminals (Scholz & Miller, 1991; Doze et al., 1995; Guyon & Leresche, 1995) .
Postsynaptic actions
In neocortical neurons of different species, electrical stimulation close to threshold or suprathreshold intensities elicits two distinguishable IPSPs (Howe et al., 1987a; Connors et al., 1988; McCormick, 1989; Luhmann & Prince, 1991) . The early IPSP is Cl --dependent and is mediated by GABA A receptors. It displays a reversal potential around -70 mV and is associated with a strong increase in membrane conductance. The blockade of this IPSP by bicuculline or picrotoxin leads to the expression of paroxysmal depolarizations (Gutnick et al., 1982) . The second, late IPSP is potassium dependent (Howe et al., 1987a; Connors et al., 1988; McCormick, 1989; van Brederode & Spain, 1995) with a reversal potential around -90 to -95 mV. The accompanying increase in membrane conductance is less pronounced compared to that of GABA A receptor-mediated IPSPs. This late IPSP is mediated by GABA B receptors because it is reversibly blocked by the GABA B receptor antagonists phaclofen, 2-OH-saclofen and CGP 35348 (McCormick, 1989; Metherate & Ashe, 1994; van Brederode & Spain, 1995) . These characteristics of late IPSPs have also been observed in other regions of the CNS including the hippocampus and thalamus (see table 1 in Misgeld et al., 1995) . Application of the GABA B receptor agonist baclofen induces a potassium-dependent hyperpolarization associated with an increase in membrane conductance (see table 1 in Misgeld et al., 1995) . In the present study, this action of baclofen could be reversibly reduced or blocked by comparatively low concentrations (30-100 µM) of CGP 35348 (see Fig. 3 ), thus confirming observations reported by Deisz et al. (1997) that low concentrations of CGP 35348 are sufficient to efficiently reduce GABA B receptor-mediated postsynaptic inhibition.
In line with studies from other laboratories (Dutar & Nicoll, 1988; Karlsson & Olpe, 1989; Karlsson et al., 1992; Olpe et al., 1990; Scanziani et al., 1991) , we observed that, in contrast to a suppression of GABA A receptor-mediated inhibition, blockade of GABA B receptors alone did not induce epileptiform activity. Thus, under normal conditions, excitatory synaptic transmission seems to be controlled predominantly by GABA A receptor-mediated IPSPs, and a reduction in GABA B receptor-dependent IPSPs in the presence of intact GABA A receptor-mediated mechanisms is insufficient to evoke epileptiform activity. Metherate & Ashe (1994) reported a facilitation of NMDA receptor-mediated late EPSPs by paired-pulse stimulation in rat neocortical neurons in vivo and in vitro. This facilitation was due to the reduction of both the early and late IPSP. Even following a decrease in the efficacy of GABA A receptor-mediated inhibition by paired-pulse stimulation in the presence of the GABA B receptor antagonist 2-OH-saclofen, the neurons did not generate epileptiform potentials, suggesting that only a substantial reduction in GABA A receptor-dependent inhibition leads to the initiation of paroxysmal depolarization. However, as shown by Chagnac-Amitai & Connors (1989) , the spread of epileptiform activity may occur in the presence of low bicuculline concentrations (Ͻ 0.5 µM), i.e. in the presence of relatively intact GABA A receptor-mediated synaptic transmission.
Following disinhibition of the slices using the GABA A receptor antagonists bicuculline and picrotoxin, we observed a marked potentiation of epileptiform activity upon application of CGP 35348. This potentiation could be partially reduced by D-2-APV, indicating that GABA B receptors limit epileptiform activity by suppressing delayed NMDA receptor-mediated excitatory mechanisms. It is important to point out that this statement is only valid for epileptiform activity generated by blockade of GABA A receptors/channels with bicuculline or picrotoxin. CGP 35348 did not influence epileptiform activity which was produced by the removal of Mg 2ϩ from the bathing solution. Thus, under the conditions of strongly potentiated glutamatergic synaptic transmission, both GABAergic systems lose control over neocortical excitability.
The magnitude of the effect of CGP 35348 on bicuculline-induced epileptiform activity did not differ between different cortical layers. In cat neocortex, a spatial difference in the distribution of efficient GABA B receptor-mediated inhibition has been described by intracellular recordings (van Brederode & Spain, 1995) . This is obviously not the case in the rat neocortex. During optical recordings of epileptiform activity, a homogeneous increase in signal area was observed at all recording sites following the addition of CGP 35348 to the bathing solution. Intracellular recordings showed that efficient late IPSPs could be evoked in neurons of both superficial as well as deep layers of the rat neocortex (B. Sutor, unpublished observation).
The pro-convulsive effect of GABA B receptor blockade which we observed in disinhibited slices is in agreement with previous studies performed in rat hippocampal slices (Karlsson et al., 1992; Scanziani et al., 1991; but see Domann et al., 1991) . In the presence of low bicuculline concentrations (2-4 µM), Scanziani et al. (1991) described a large GABA B receptor-mediated so-called paroxysmal inhibitory potential that was suppressed by CGP 35348. Using higher bicuculline concentrations, Karlsson et al. (1992) observed an increase in spontaneous epileptiform burst discharges in the CA3 region of the hippocampus in vitro following exposure of disinhibited slices to 100 µM CGP 35348. Similar observations were reported by Scanziani et al. (1994) . These results together with our own data suggest that under the conditions of reduced GABA A receptor function, GABA B receptormediated postsynaptic inhibition may act as an 'intrinsic safety factor' which prevents the occurrence of severe seizure activity (for review see Thompson, 1994) . It should be pointed out that CGP 35348 did not act pro-convulsively in some epilepsy models in vivo. The GABA B receptor antagonist facilitated convulsions generated by isoniazid (blocker of glutamate decarboxylase), but did not affect pentylenetetrazol-, picrotoxin-or strychnine-induced convulsions; the effects on bicuculline-evoked convulsions were inconsistent (Karlsson et al., 1992) . CGP 35348 applied systemically during in vivo experiments certainly influences the function of all those brain areas which express GABA B receptors. Thus, the overall effect of the drug depends on the interaction of these areas in the presence and absence of CGP 35348.
Presynaptic action
In addition to the pro-convulsive action of CGP 35348 mediated by an inhibition of postsynaptic GABA B receptors in disinhibited slices, we observed, under certain experimental conditions, an anticonvulsant effect of the antagonist. At stimulation using threshold intensity and in the presence of bicuculline, CGP 35348 (30-100 µM) caused intermittent failures of epileptiform discharges which resulted in the complete suppression of bicuculline-induced epileptiform activity. Because failures of bicuculline-induced epileptiform responses occurred only following stimulation at threshold intensity but not at suprathreshold stimulus intensities, prolonged refractoriness can be excluded as the reason for the block of epileptiform activity.
CGP 35348-induced failures of epileptiform discharges were seen in all slices in which the competitive GABA A receptor antagonist bicuculline was used to block synaptic inhibition. In slices in which picrotoxin was applied or in which extracellular magnesium ions were removed, the failure rate was considerably lower, or we observed no failures at all. In the presence of picrotoxin and CGP 35348, we observed long-lasting repetitive discharges of epileptiform field potentials alternating with one-three failures (see Fig. 5C ). In the case of picrotoxin, we assume a prolonged refractoriness due to longlasting discharges to be the main reason for failures of epileptiform activity.
The blockade of GABA uptake systems by nipecotic acid partially mimicked the action of CGP 35348, as far as it induced response failures and a depression of epileptiform activity in slices disinhibited by application of bicuculline, but not in those in which picrotoxin was used. Thus, the response failures and inhibition of epileptiform activity seen under the given experimental conditions are most probably due to an increase in the effective amount of GABA present in the extracellular space following stimulation.
The action of GABA on presynaptic GABA B receptors is well established. Activation of these receptors decreases presynaptic release of both glutamate and GABA, thereby reducing glutamatergic EPSPs and GABAergic IPSPs (for review see Misgeld et al., 1995) . The GABA B receptor-mediated control of GABA release has been extensively studied in different areas of the brain (Pittaluga et al., 1987; Harrison, 1990; Scholz & Miller, 1991; Otis & Mody, 1992; Isaacson et al., 1993; Lambert & Wilson, 1993; Doze et al., 1995; Guyon & Leresche, 1995; Khazipov et al., 1995; Emri et al., 1996; Mouginot & Gähwiler, 1996; Radnikow et al., 1997) . In the rat cerebral cortex, the GABA B receptor agonist baclofen reduced GABA release measured using [ 3 H]GABA-prelabelled synaptosomes (Pittaluga et al., 1987) indicating the presence of GABA B receptors on GABAergic nerve terminals. The inhibitory effect of GABA B receptor activation on transmitter release is most probably due to the reduction of the conductance of presynaptic calcium channels (Scholz & Miller, 1991; Doze et al., 1995; Guyon & Leresche, 1995) . Recent studies suggest that there may be different GABA B receptor subtypes involved in the presynaptic action of GABA (Harrison, 1990; Guyon & Leresche, 1995; Emri et al., 1996) . Furthermore, it has been shown that there are subsets of GABAergic interneurons insensitive to presynaptic control of transmitter release by GABA (Lambert & Wilson, 1993; Radnikow et al., 1997) , and that GABA B receptors do not influence spontaneous transmitter release or GABA release induced by so-called minimal stimulation (Otis & Mody, 1992; Doze et al., 1995; Radnikow et al., 1997) . In the rat neocortex, application of the GABA B receptor agonist baclofen reduces the amplitude of postsynaptic responses consisting of both EPSPs and IPSPs (Howe et al., 1987b) . In the present study, we showed that CGP 35348 (100-300 µM) is able to prevent this action of baclofen (see Fig. 3 ), indicating the presence of CGP 35348-sensitive GABA B receptors on GABAergic interneurons which are activated by the stimuli applied and which contribute to the EPSP/IPSP-sequences recorded. The anticonvulsant effect of CGP 35348 could be observed only at low stimulus intensities (close to threshold) and most probably results from the blockade of these GABA B receptors. The consequence is a prevention of the presynaptic auto-inhibition and an increase in GABA release. The increased GABA concentration at the GABA A receptor binding site might then facilitate the dissociation of bicuculline from the receptor. This explanation is substantiated by the finding that the anticonvulsant effect is mimicked by a pharmacologically induced increase in extracellular GABA concentration and by the observation that the effect is not observed in the presence of the noncompetitive GABA A receptor antagonist picrotoxin.
A further clarification of the differential role of presynaptic versus postsynaptic GABA B receptors is so far hampered by the lack of selective antagonists able to distinguish between different GABA B receptor subtypes (Bonanno & Raiteri, 1993) . Our observations suggest that GABA B receptor antagonists selectively acting at presynaptic receptors might be most beneficial in controlling seizure activity which is generated by a dysfunction of GABAergic mechanisms. In © 1998 European Neuroscience Association, European Journal of Neuroscience, 10, 3417-3427 a model of chronic temporal lobe epilepsy, GABA A receptor-mediated IPSPs do not display a frequency-dependent decline in the amplitude, probably due to presynaptic GABA B receptor dysfunction (Mangan & Lothman, 1996) . A frequency-dependent decrease in the efficiency of GABA A receptor-mediated inhibition during epileptiform discharges certainly potentiates epileptiform activity. GABA B receptor antagonists selective for presynaptic GABA B receptors might act anti-convulsive by preventing this rundown of GABA A receptormediated inhibition.
